Who is sponsoring NCT02255565?

NCT02255565 is sponsored by Seattle Children's Hospital.

What condition does NCT02255565 study?

NCT02255565 studies ADHD, Autism.

What drugs are being tested in NCT02255565?

Interventions: Very Low Dose Quillivant XR, Low Dose Quillivant XR, Moderate Dose Quillivant XR.

What is the status of NCT02255565?

NCT02255565 is currently COMPLETED.

Last reviewed 2017-07-03 · How we verify

Quillivant XR in Children With Attention Deficit/Hyperactivity Disorder (ADHD) and Autism Spectrum Disorder (ASD): A Pilot Study

NCT02255565 Phase 4 COMPLETED Results posted

The purpose of this study is to determine whether Quillivant XR is effective in the treatment of ADHD in children with Autism Spectrum Disorder (ASD).

Details

Lead sponsor	Seattle Children's Hospital
Phase	Phase 4
Status	COMPLETED
Enrolment	36
Start date	2014-09
Completion	2016-10

Conditions

ADHD
Autism

Interventions

Very Low Dose Quillivant XR
Low Dose Quillivant XR
Moderate Dose Quillivant XR

Primary outcomes

ADHD Rating Scale - IV — once a week for 6 weeks
Measures the severity of Total ADHD symptoms, Inattention and Hyperactivity/Impulsive symptoms. The Inattention and Hyperactivity/Impulsive symptoms can range from 0 to 27 each, with a higher score reflecting more severe ADHD symptoms. The total score is calculated by summing the inattention and Hyperactivity/Impulsive subscales. The total score can range from 0 to 54 with a higher score reflecting more severe ADHD symptoms.

Countries

United States